Effect of fondaparinux sodium in the prevention of deep vein thromboembolism after surgery on lower limbs
10.3969/j.issn.1005-1678.2016.08.016
- VernacularTitle:磺达肝葵钠对下肢术后患者深静脉血栓栓塞的影响
- Author:
Wei SU
;
Lili ZHANG
- Publication Type:Journal Article
- Keywords:
deep vein thromboembosis;
fondaparinux sodium;
rivaroxaban
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(8):68-70
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of fondaparinux sodium in the treat of deep vein thromboembolism after the surgery on lower limbs.Methods 83 cases of patients with lower extremity surgery from Jan 2013 to May 2015,were randomly divided into experimental group(42 cases) and control group(41 cases),the patients in experimental group were injected subcutaneously with fondaparinux sodium 2.5 mg,one time a day,for five days and the patients of control group administrated orally with rivaroxaban 10 mg, one time a day, for five days.All patients accepted the ultrasonic examination by Doppler’ s method before the experiment, seven days and one month later after the experiment.The occurrence of deep vein thromboembolism of all patients was counted,including Proximal thrombosis,Distal thrombosis and Total venous thrombosis,and recorded the occurrence of adverse reaction-subcutaneous hemorrhage.Results One case(2.38%)of deep vein thrombosis was appeared in the experimental group,and that was significantly lower than that of the control group seven case ( 17.07%, P <0.05 ) .Meanwhile, there was no patient observed adverse reaction in experimental group, while two cases were observed in control group ( P <0.05 ) .Conclusion Fondaparinux showed better clinical efficacy than rivaoxaban,and caused fewer adverse reaction.We can conclude that it is safe and effective for the treatment of deep vein thrombosis in patients accepting the lower limbs surgery.
